171 related articles for article (PubMed ID: 33135721)
21. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition.
Tirosh A; Killian JK; Petersen D; Zhu YJ; Walker RL; Blau JE; Nilubol N; Patel D; Agarwal SK; Weinstein LS; Meltzer P; Kebebew E
J Clin Endocrinol Metab; 2020 Oct; 105(10):3285-94. PubMed ID: 32706863
[TBL] [Abstract][Full Text] [Related]
22. Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life.
Gonçalves TD; Toledo RA; Sekiya T; Matuguma SE; Maluf Filho F; Rocha MS; Siqueira SA; Glezer A; Bronstein MD; Pereira MA; Jureidini R; Bacchella T; Machado MC; Toledo SP; Lourenço DM
J Clin Endocrinol Metab; 2014 Jan; 99(1):E89-96. PubMed ID: 24178797
[TBL] [Abstract][Full Text] [Related]
23. Multiple endocrine neoplasia type 1 syndrome: single centre experience from western India.
Goroshi M; Bandgar T; Lila AR; Jadhav SS; Khare S; Shrikhande SV; Uchino S; Dalvi AN; Shah NS
Fam Cancer; 2016 Oct; 15(4):617-24. PubMed ID: 26905068
[TBL] [Abstract][Full Text] [Related]
24. Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.
Faggiano A; Ferolla P; Grimaldi F; Campana D; Manzoni M; Davì MV; Bianchi A; Valcavi R; Papini E; Giuffrida D; Ferone D; Fanciulli G; Arnaldi G; Franchi GM; Francia G; Fasola G; Crinò L; Pontecorvi A; Tomassetti P; Colao A
J Endocrinol Invest; 2012 Oct; 35(9):817-23. PubMed ID: 22080849
[TBL] [Abstract][Full Text] [Related]
25. Expression of p27
Conemans EB; Raicu-Ionita GM; Pieterman CRC; Dreijerink KMA; Dekkers OM; Hermus AR; de Herder WW; Drent ML; van der Horst-Schrivers ANA; Havekes B; Bisschop PH; Offerhaus GJ; Borel Rinkes IHM; Valk GD; Timmers HTM; Vriens MR
J Endocrinol Invest; 2018 Jun; 41(6):655-661. PubMed ID: 29134609
[TBL] [Abstract][Full Text] [Related]
26. Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors.
Kfir SK; Halperin R; Percik R; Uri I; Halpern N; Shlomai G; Laish I; Tirosh A; Tirosh A
Horm Metab Res; 2021 May; 53(5):319-325. PubMed ID: 33878789
[TBL] [Abstract][Full Text] [Related]
27. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines.
Goudet P; Dalac A; Le Bras M; Cardot-Bauters C; Niccoli P; Lévy-Bohbot N; du Boullay H; Bertagna X; Ruszniewski P; Borson-Chazot F; Vergès B; Sadoul JL; Ménégaux F; Tabarin A; Kühn JM; d'Anella P; Chabre O; Christin-Maitre S; Cadiot G; Binquet C; Delemer B
J Clin Endocrinol Metab; 2015 Apr; 100(4):1568-77. PubMed ID: 25594862
[TBL] [Abstract][Full Text] [Related]
28. Multiple endocrine neoplasia type 1 (MEN1): its manifestations and effect of genetic screening on clinical outcome.
Pieterman CR; Schreinemakers JM; Koppeschaar HP; Vriens MR; Rinkes IH; Zonnenberg BA; van der Luijt RB; Valk GD
Clin Endocrinol (Oxf); 2009 Apr; 70(4):575-81. PubMed ID: 18616711
[TBL] [Abstract][Full Text] [Related]
29. Pituitary adenomas in the setting of multiple endocrine neoplasia type 1: a single-institution experience.
Cohen-Cohen S; Brown DA; Himes BT; Wheeler LP; Ruff MW; Major BT; Singh Ospina NM; Atkinson JLD; Meyer FB; Bancos I; Young WF; Van Gompel JJ
J Neurosurg; 2020 Apr; 134(3):1132-1138. PubMed ID: 32244213
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG).
de Laat JM; Dekkers OM; Pieterman CR; Kluijfhout WP; Hermus AR; Pereira AM; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; de Herder WW; Valk GD
J Clin Endocrinol Metab; 2015 Sep; 100(9):3288-96. PubMed ID: 26126205
[TBL] [Abstract][Full Text] [Related]
31. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression.
Fahrmann JF; Wasylishen AR; Pieterman CRC; Irajizad E; Vykoukal J; Murage E; Wu R; Dennison JB; Krishna H; Peterson CB; Lozano G; Zhao H; Do KA; Halperin DM; Agarwal SK; Blau JE; Del Rivero J; Nilubol N; Walter MF; Welch JM; Weinstein LS; Vriens MR; van Leeuwaarde RS; van Treijen MJC; Valk GD; Perrier ND; Hanash SM
J Clin Endocrinol Metab; 2021 Nov; 106(12):e4969-e4980. PubMed ID: 34318891
[TBL] [Abstract][Full Text] [Related]
32. Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression.
Walls GV; Stevenson M; Soukup BS; Lines KE; Grossman AB; Schmid HA; Thakker RV
Endocrinology; 2016 May; 157(5):1789-98. PubMed ID: 26990064
[TBL] [Abstract][Full Text] [Related]
33. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.
Bartsch DK; Slater EP; Albers M; Knoop R; Chaloupka B; Lopez CL; Fendrich V; Kann PH; Waldmann J
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2387-91. PubMed ID: 25210877
[TBL] [Abstract][Full Text] [Related]
34. ARMC5 Alterations in Patients With Sporadic Neuroendocrine Tumors and Multiple Endocrine Neoplasia Type 1 (MEN1).
Damjanovic SS; Antic JA; Elezovic-Kovacevic VI; Dundjerovic DM; Milicevic IT; Beleslin-Cokic BB; Ilic BB; Rodic GS; Berthon A; Maria AG; Faucz FR; Stratakis CA
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4531-42. PubMed ID: 32901291
[TBL] [Abstract][Full Text] [Related]
35. Thymic neuroendocrine tumors in multiple endocrine neoplasia type 1: a comparative study on 21 cases among a series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines).
Goudet P; Murat A; Cardot-Bauters C; Emy P; Baudin E; du Boullay Choplin H; Chapuis Y; Kraimps JL; Sadoul JL; Tabarin A; Vergès B; Carnaille B; Niccoli-Sire P; Costa A; Calender A;
World J Surg; 2009 Jun; 33(6):1197-207. PubMed ID: 19294466
[TBL] [Abstract][Full Text] [Related]
36. Surgery for a gastroenteropancreatic neuroendocrine tumor (GEPNET) in multiple endocrine neoplasia type 1.
Hanazaki K; Sakurai A; Munekage M; Ichikawa K; Namikawa T; Okabayashi T; Imamura M
Surg Today; 2013 Mar; 43(3):229-36. PubMed ID: 23076685
[TBL] [Abstract][Full Text] [Related]
37. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form.
Gibril F; Venzon DJ; Ojeaburu JV; Bashir S; Jensen RT
J Clin Endocrinol Metab; 2001 Nov; 86(11):5282-93. PubMed ID: 11701693
[TBL] [Abstract][Full Text] [Related]
38. Surgery for multiple endocrine neoplasia type 1-related insulinoma: long-term outcomes in a large international cohort.
van Beek DJ; Nell S; Verkooijen HM; Borel Rinkes IHM; Valk GD; ; Vriens MR;
Br J Surg; 2020 Oct; 107(11):1489-1499. PubMed ID: 32352164
[TBL] [Abstract][Full Text] [Related]
39. Well-Differentiated Bronchopulmonary Neuroendocrine Tumors: More Than One Entity.
van den Broek MFM; Levy S; Buikhuisen WA; Dijke K; Hartemink KJ; van Leeuwaarde RS; Vriens MR; Tesselaar MET; Valk GD;
J Thorac Oncol; 2021 Nov; 16(11):1810-1820. PubMed ID: 34352379
[TBL] [Abstract][Full Text] [Related]
40. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors.
Nell S; Borel Rinkes IHM; Verkooijen HM; Bonsing BA; van Eijck CH; van Goor H; de Kleine RHJ; Kazemier G; Nieveen van Dijkum EJ; Dejong CHC; Valk GD; Vriens MR;
Ann Surg; 2018 Feb; 267(2):352-356. PubMed ID: 27811505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
